Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | LHCGR | P22888 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.75 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.75 |
| ▸ | MGLL | Q99685 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393643 | 1.00 | FAAH (1.00) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089418 | 0.99 | FAAH (0.97) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089399 | 0.93 | FAAH (0.88) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089404 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089402 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089406 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089403 | 0.88 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089425 | 0.88 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089426 | 0.88 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.87 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085674-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS | BACAINN THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-2598477-B1 | PERIPHERALLY RESTRICTED FAAH INHIBITORS | UNIV CALIFORNIA (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9187413-B2 | Peripherally restricted FAAH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-17 | — | — | US | disclosed |
| EP-1558591-B1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | UNIV CALIFORNIA (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20130217764-A1 | PERIPHERALLY RESTRICTED FAAH INHIBITORS | UNIVERSITA DEGLI STUDI DI URBINO (IT) | 2013-08-22 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476043-B2 | Inhibitors for the soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2598477-A2 | PERIPHERALLY RESTRICTED FAAH INHIBITORS | The Regents of the University of California (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015704-A2 | PERIPHERALLY RESTRICTED FAAH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-12 | — | — | US | disclosed |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1558591-A4 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | UNIV CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176201-B2 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1742626-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | The Regents of The University of California (US) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005115370-A2 | COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-08 | — | — | WO | disclosed |
| EP-1558591-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | The Regents of the University of California (US) | 2005-08-03 | — | — | EP | disclosed |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| WO-2004033422-A2 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217764-A1 | PERIPHERALLY RESTRICTED FAAH INHIBITORS | FAAH, FAAH2, CNR2 | FAAH 1/4885LHCGR 2543/4885ALDH1A1 623/4885 |
| US-20080103209-A1 | Compounds And Methods For Treating Non-Inflammatory Pain Using Ppar Alpha Agonists | FAAH, CNR2, FAAH2 | FAAH 1/4885LHCGR 1710/4885ALDH1A1 967/4885 |
| US-20120010283-A1 | MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | FAAH, FAAH2, CNR2 | FAAH 1/4885LHCGR 1617/4885ALDH1A1 734/4885 |
| US-20040127518-A1 | Modulation of anxiety through blockade of anandamide hydrolysis | FAAH, FAAH2, CNR2 | FAAH 1/4885LHCGR 1910/4885ALDH1A1 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.